Loading
Primary cutaneous marginal zone lymphoma is a very slow-growing lymphoma that appears as pink or purple lumps in the skin, usually on the arms or trunk, and almost never spreads inside the body. WHO-HAEM5 now calls it a lymphoproliferative disorder because it behaves so well; surgery or radiotherapy clears most lesions, and relapses in the skin are common but harmless.
WHO-HAEM5 renamed this entity primary cutaneous marginal zone lymphoproliferative disorder to reflect its indolent behaviour, keeping it beside the other marginal zone lymphomas; it was once called immunocytoma because of its plasmacytic differentiation (Alaggio 2022). In 137 patients, 51 percent had a solitary lesion, 29 percent regional and 20 percent generalised skin disease; surgical excision, local radiotherapy or both were the initial treatment in 86 percent, complete remission followed in 88 percent (93 percent of solitary or localised and 71 percent of multifocal cases), and cutaneous relapses occurred in 44 percent without loss of survival (J Am Acad Dermatol 2013). Unlike other marginal zone lymphomas, 39 percent of primary cutaneous cases with plasmacytic differentiation express IgG4, the highest rate in any B-cell lymphoma, against 1 of 120 non-cutaneous cases (Modern Pathology 2013).
How it differs from its parent: it is confined to the skin at diagnosis, is treated by dermatologists with excision or radiotherapy rather than systemic therapy, and its relapses are skin-only; extracutaneous spread is the exception. Borrelia infection has been implicated in some European cases.
How common: no registry share in the sources read.
Treatment: excision or low-dose radiotherapy for solitary or localised lesions; observation, intralesional steroids or rituximab for multifocal disease; systemic therapy only for the rare extracutaneous spread, following the parent page (J Am Acad Dermatol 2013; Zucca 2020).
Rare and indolent; the largest clinical series holds 137 patients, 51 percent presenting with a solitary lesion (J Am Acad Dermatol 2013). No registry share is in the sources read.
Leukaemias, myeloma and MDS live in the marrow and blood; lymphomas grow in lymph nodes and spleen. The node stations are the disease map, not a route of spread, and staging counts them.
In lymphoma the node stations are the disease itself; staging (Ann Arbor / Lugano) counts how many regions and sides of the diaphragm are involved.
Same organ: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), Splenic marginal zone lymphoma, Nodal marginal zone lymphoma, Primary cutaneous follicle centre lymphoma, Sezary syndrome, Nodal T-follicular helper cell lymphoma, angioimmunoblastic type (angioimmunoblastic T-cell lymphoma), Hepatosplenic T-cell lymphoma, Intravascular large B-cell lymphoma, Lymphomatoid granulomatosis, T-cell prolymphocytic leukaemia, Splenic B-cell lymphoma/leukaemia with prominent nucleoli (formerly B-cell prolymphocytic leukaemia and hairy cell leukaemia variant), T-cell large granular lymphocytic leukaemia, Mixed-phenotype acute leukaemia, Myeloid leukaemia of Down syndrome, Burkitt leukaemia, Marginal zone lymphoma, Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome), Primary mediastinal (thymic) large B-cell lymphoma, Leukaemia (all types), Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia, Chronic myeloid leukaemia (CML), Diffuse large B-cell lymphoma, Follicular lymphoma, Hodgkin lymphoma, Mantle cell lymphoma, Multiple myeloma, Non-Hodgkin lymphoma (all types), Myelodysplastic syndromes / neoplasms (MDS), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Polycythaemia vera (PV), Essential thrombocythaemia (ET), Waldenström macroglobulinaemia, Hairy cell leukaemia, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Burkitt lymphoma, HIV-associated (AIDS-related) lymphomas, Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, Systemic mastocytosis, Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms, Langerhans cell histiocytosis (LCH), Post-transplant lymphoproliferative disorder (PTLD), FLT3-mutated acute myeloid leukaemia, IDH1- and IDH2-mutated acute myeloid leukaemia, NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia, Secondary and therapy-related acute myeloid leukaemia, Acute promyelocytic leukaemia, Acute myeloid leukaemia in older or unfit patients, Smouldering multiple myeloma, Newly diagnosed multiple myeloma, transplant-eligible, Newly diagnosed multiple myeloma, transplant-ineligible, Relapsed or refractory multiple myeloma, Plasma cell leukaemia, Lower-risk myelodysplastic syndromes, Higher-risk myelodysplastic syndromes, Chronic lymphocytic leukaemia, first treatment, Relapsed or refractory chronic lymphocytic leukaemia, Richter transformation of chronic lymphocytic leukaemia, Chronic myeloid leukaemia, chronic phase, Chronic myeloid leukaemia, accelerated and blast phase, Primary myelofibrosis, Standard-risk B-cell acute lymphoblastic leukaemia in children, High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL), Philadelphia chromosome-positive acute lymphoblastic leukaemia in children (Ph-positive ALL), Philadelphia chromosome-like acute lymphoblastic leukaemia (Ph-like or BCR::ABL1-like ALL), Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year), Relapsed and refractory acute lymphoblastic leukaemia in children, Acute myeloid leukaemia in children, Erdheim-Chester disease, Rosai-Dorfman-Destombes disease, Single-system Langerhans cell histiocytosis (bone, skin or one other organ), Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement), Indolent and smouldering systemic mastocytosis, Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia), Early-stage classical Hodgkin lymphoma (stage I to II), Advanced-stage classical Hodgkin lymphoma (stage III to IV), Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma), Relapsed and refractory classical Hodgkin lymphoma
Observation, intralesional steroids or rituximab; systemic therapy only for extracutaneous spread.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this cancer: (TITLE:"Primary cutaneous marginal zone lymphoma" OR ABSTRACT:"Primary cutaneous marginal zone lymphoma" OR TITLE:"Primary cutaneous marginal zone B-cell lymphoma" OR ABSTRACT:"Primary cutaneous marginal zone B-cell lymphoma" OR TITLE:"Primary cutaneous marginal zone lymphoproliferative disorder" OR ABSTRACT:"Primary cutaneous marginal zone lymphoproliferative disorder" OR TITLE:"Primary cutaneous immunocytoma" OR ABSTRACT:"Primary cutaneous immunocytoma" OR TITLE:"Cutaneous immunocytoma" OR ABSTRACT:"Cutaneous immunocytoma" OR TITLE:"PCMZL" OR ABSTRACT:"PCMZL") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Primary cutaneous marginal zone lymphoma, not a curated reading list.
The targets of this cancer's medicines and the ones linked to it directly.
Cases by country, the UK and NHS pathway and other country lenses, and the expert centres with trials on record.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
A shortage of antibodies because treatment has wiped out the B cells or plasma cells that make them, as CD19 CAR-T, CD20 antibodies and BCMA therapies deliberately do. It leaves patients prone to infections, sometimes for years, and is managed with immunoglobulin infusions.
Reactions around the moment a drug is given: chills, fever or breathlessness from antibodies (infusion reactions), true allergy (hypersensitivity, rarely anaphylaxis), and leakage of a damaging drug into tissue around the vein (extravasation).
See all on the product pages:Rituximab·Printable cards in the navigator
Newly diagnosed? Read the first 60 days with Primary cutaneous marginal zone lymphoma, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
Every connected record, the notes, the JSON, Markdown and RDF twins, and where the record came from and when it was checked.